Exorex Lotion 5% V/W Cutaneous Emulsion
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Exorex Lotion 5% v/w Cutaneous Emulsion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
The active ingredient is coal tar solution 5% v/w.
Excipients:
Methyl hydroxybenzoate (E218)0.10% w/w Propyl hydroxybenzoate (E216) 0.05% w/w Hydrogenated polyoxyl castor oil 0.45% w/w
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous emulsion A smooth mustard coloured emulsion.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Exorex is for the treatment of psoriasis of the skin and scalp.
4.2 Posology and method of administration Adults and children over 12 years of age
Ensure that the lesions are clean, Apply a thin layer of Exorex two to three times per day to the affected areas. Massage gently and leave to dry.
For young children under 12 years of age and the elderly
The emulsion may be diluted by mixing with a few drops of freshly boiled and cooled water in the palm of the hand.
4.3
Contraindications
Do not use if sensitive to any of the ingredients.
Presence of folliculitis and acne vulgaris.
Exorex should not be used on patients who have disease characterised by photosensitivity such as lupus erythematosus or allergy to sunlight.
Exorex should not be applied to inflamed or broken skin (open exuding wounds or infection of the skin).
4.4 Special warnings and precautions for use
Coal tar may cause skin irritation. If irritation occurs, the treatment should be reviewed and discontinued if necessary.
Coal tar enhances photosensitivity of the skin, and exposure to direct sunlight after application of Exorex should be avoided.
Use with care near the eyes and mucous membranes. If any emulsion should accidentally enter the eye, flush with normal saline solution or water.
Do not apply to genital and rectal areas.
Apply with caution to the face.
Hydrogenated polyoxyl castor oil may cause skin reactions. Methyl and propyl hydroxybenzoates may cause allergic reactions that might be delayed.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Pregnancy and lactation
There is inadequate evidence of safety in pregnant and lactating women but coal tar preparations have been in use for many years without apparent ill-consequence and no harmful effects on the health of the child is anticipated with the proper use of this product. However, it is recommended that the use of coal tar in pregnancy and lactation be restricted to intermittent use, in a low concentration on a relatively small percentage of body surface and that use during the first trimester be avoided.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Skin and subcutaneous tissue disorders:
Skin irritation, photosensitivity of the skin. In addition coal tar may cause acne-like eruptions of the skin.
An increased risk of skin cancer in psoriatic patients treated with a combination of coal tar and UVB radiation has been reported. However epidemiological studies of patients treated with coal tar alone are inconclusive. The risk of toxicity should be taken into account when considering the suitability of this product for the patient (see also Section 5.3).
4.9 Overdose
There is no evidence that overdose of topical Exorex would be harmful other than possibly inducing a hypersensitivity to coal tar. Ingestion of Exorex may require gastric lavage depending on the quantity taken and should be treated symptomatically.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Exorex contains coal tar, an antipruritic and keratoplastic. It is used in eczema, psoriasis and other skin conditions. Tar acids have also been shown to have disinfectant properties. Exorex may be used alone, or as part of a more extensive treatment regimen.
5.2 Pharmacokinetic properties
Not applicable.
5.3 Preclinical safety data
In animal studies coal tar has been shown to increase the incidence of epidermal carcinomas and self-limiting keratoacanthomas.
While the ingredients of coal tar have been shown to express genotoxic properties, epidemiological studies with patients have been shown to be inconclusive concerning the potential carcinogenic risks of coal tar products in human long term treatment. Nevertheless the possible risk of prolonged treatment should be taken into account when considering the usage of the product.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
dl-Alpha tocopherol Vitamin F ethyl ester Xanthan gum
Propyl hydroxybenzoate (E216)
Methyl hydroxybenzoate (E218)
Hydrogenated polyoxyl castor oil Purified water
6.2 Incompatibilities
Not applicable.
Shelf life
6.3
2 years
6.4 Special precautions for storage
Do not store above 25 °C
6.5 Nature and contents of container
High density polyethylene bottle containing titanium dioxide. Polypropylene green flip-top caps.
Pack sizes: 100 and 250ml
A professional sales pack of 30ml is also available.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Shake the bottle before use.
7 MARKETING AUTHORISATION HOLDER
Forest Tosara Limited Baldoyle Industrial Estate Grange Road Dublin 13 Ireland
8 MARKETING AUTHORISATION NUMBER(S)
PL 06166/0001
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
23/05/2007
10
DATE OF REVISION OF THE TEXT
23/05/2007